Xenon Pharmaceuticals (XENE) Receivables - Other (2019 - 2026)

Xenon Pharmaceuticals (XENE) has 4 years of Receivables - Other data on file, last reported at $1.2 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $1.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (changed N/A YoY), and the FY2025 annual result was $1.4 million, down 6.67% from the prior year.
• Receivables - Other declined to $1.2 million in Q1 2026 per XENE's latest filing, from $1.4 million in the prior quarter.
• Over five years, Receivables - Other peaked at $1.5 million in Q4 2024 and troughed at $812000.0 in Q3 2025.
• A 3-year average of $1.2 million and a median of $1.2 million in 2026 frame the typical range for Receivables - Other.
• On a YoY basis, Receivables - Other climbed as much as 6.67% in 2025 and fell as far as 6.67% in 2025.
• A 3-year view of Receivables - Other shows it stood at $1.5 million in 2024, then slipped by 6.67% to $1.4 million in 2025, then fell by 15.03% to $1.2 million in 2026.
• Business Quant data shows XENE's Receivables - Other at $1.2 million in Q1 2026, $1.4 million in Q4 2025, and $812000.0 in Q3 2025.